Källén B, Knudsen L B, Mutchinick O, Mastroiacovo P, Lancaster P, Castilla E, Robert E
Department of Embryology, University of Lund, Sweden.
Int J Epidemiol. 1993 Feb;22(1):107-15. doi: 10.1093/ije/22.1.107.
Using data from seven malformation monitoring systems around the world, the feasibility of monitoring fresh dominant mutations using skeletal dysplasias was explored. Based on a total of over 9.5 million births, 1500 infants with skeletal dysplasias were identified (16 per 100,000). In spite of efforts to get exact diagnoses, an average of 21% were unspecified. Comparisons of rates of specific diagnoses in different programmes suggested that classification differed. By analysing maternal age distribution, estimates were made of the proportion of fresh mutations in different subgroups: conditions regarded as dominant (achondroplasia, thanatophoric dysplasia, spondyloepiphyseal dysplasia) were estimated to consist of 58% fresh mutations--some of the remaining cases were inherited, others were probably misclassified. Among conditions regarded as recessive, only 5% were estimated to be truly dominant mutations. In the total group of skeletal dysplasias, 21% were estimated to be fresh dominant mutations and if osteogenesis imperfecta were excluded, the figure was 31%. By power analyses it was shown that equal monitoring power may be obtained by a programme covering about 45,000 births per year with intensive diagnosis of each individual case of skeletal dysplasia and a programme some three times greater where no specific diagnoses are obtained. An increasing trend in the occurrence of skeletal dysplasias was seen but probably explained by changing ascertainment. An impact of antenatal diagnosis resulting in a decrease in occurrence was also apparent in some programmes.
利用来自全球七个畸形监测系统的数据,探讨了使用骨骼发育异常监测新发显性突变的可行性。基于总计超过950万例出生数据,共识别出1500例骨骼发育异常婴儿(每10万人中有16例)。尽管努力进行准确诊断,但平均仍有21%的病例诊断不明确。不同项目中特定诊断率的比较表明分类存在差异。通过分析母亲年龄分布,估计了不同亚组中新鲜突变的比例:被视为显性的疾病(软骨发育不全、致死性骨发育不全、脊椎骨骺发育不良)估计有58%为新鲜突变——其余一些病例是遗传的,其他可能是分类错误。在被视为隐性的疾病中,估计只有5%是真正的显性突变。在骨骼发育异常的总体病例中,估计有21%是新鲜显性突变,如果排除成骨不全,这一数字为31%。通过功效分析表明,一个每年覆盖约45000例出生且对每例骨骼发育异常病例进行强化诊断的项目,与一个规模约大三倍但未获得具体诊断的项目,可能具有相同的监测功效。骨骼发育异常的发生率呈上升趋势,但可能是由于诊断方法的改变所致。在一些项目中,产前诊断导致发病率下降的影响也很明显。